Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduced the risk of cardiovascular and renal outcomes in patients with type 2 diabetes (T2D), but the underlying mechanism has not been well elucidated. The circulating levels of proteins and metabolites reflect the overall state of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jia, Chang, Xiaona, Ding, Xiaoyu, He, Xueqing, Wang, Jiaxuan, Wang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694884/
https://www.ncbi.nlm.nih.gov/pubmed/38044448
http://dx.doi.org/10.1186/s13098-023-01229-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694884/
https://www.ncbi.nlm.nih.gov/pubmed/38044448
http://dx.doi.org/10.1186/s13098-023-01229-0

Ejemplares similares